A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Survival
Hisao Uejima, MD
Principal Investigator
West Japan Thoracic Oncology Group
Japan: Ministry of Health, Labor and Welfare
WJTOG0105
NCT00144053
April 2001
Name | Location |
---|